Breaking News, Collaborations & Alliances

Aridis, Hepalink Form Joint Venture

The joint subsidiary company will be named Shenzhen Arimab Biopharmaceuticals, and will work to advance AR-301 and AR-101

Aridis Pharmaceuticals has created a joint venture with Shenzhen Hepalink Pharmaceutical Group (Hepalink) to develop and gain regulatory approval for Aridis’ fully human monoclonal antibody (mAb) therapies for the greater China market.    The jointly owned subsidiary company will be named Shenzhen Arimab Biopharmaceuticals, and headquartered in China’s largest technology hub, Shenzhen.  The company will be launched with significant capital commitment to advance two of Aridis&...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters